Skip to main content
Premium Trial:

Request an Annual Quote

HTG Molecular Out of Compliance with Nasdaq Listing Requirement

NEW YORK (GenomeWeb) – HTG Molecular Diagnostics is out of compliance with a Nasdaq listing requirement, the firm said in a document filed with the US Securities and Exchange Commission on Friday.

The company said that it was notified by Nasdaq on July 31 that the market value of its listed securities did not meet the exchange's minimum standard of at least $35 million for the past 30 consecutive trading days. HTG has until Jan. 29, 2018 to regain compliance by meeting the $35 million requirement for at least 10 consecutive business days.

If the firm cannot regain compliance between then, it will receive a delisting determination from Nasdaq. HTG would be able to appeal the determination to a Nasdaq Hearings Panel, the company said.

Shares of HTG closed at $2.24 on Friday. Its market value was $21.3 million based on 9.53 million shares outstanding. 

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.